A new method to quickly and safely reduce allergic reactions caused by IgE.
Rapid, safe suppression of IgE-mediated disease with monovalent anti-ceRIa mAb
This study is exploring a new way to help people with allergies by using a special antibody to make their immune cells less reactive to allergens, which could help prevent serious allergic reactions like anaphylaxis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10645062 on NIH RePORTER |
What this research studies
This research investigates a novel approach to rapidly desensitize immune cells involved in allergic reactions, specifically targeting the high affinity IgE receptor on mast cells and basophils. By using a specific monoclonal antibody, the study aims to make these cells temporarily unresponsive to allergens, potentially preventing severe allergic reactions like anaphylaxis. The methodology involves administering increasing doses of the antibody to achieve sustained desensitization without the adverse effects associated with traditional allergen exposure. This could provide a safer alternative for individuals with IgE-mediated allergies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with IgE-mediated allergies, particularly those at risk for anaphylaxis.
Not a fit: Patients with non-IgE-mediated allergies or those who do not experience severe allergic reactions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a rapid and safe treatment option for patients suffering from severe allergies and anaphylaxis.
How similar studies have performed: Previous research has shown promising results with similar approaches in animal models, indicating potential for success in human applications.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Finkelman, Fred Douglass — University of Cincinnati
- Study coordinator: Finkelman, Fred Douglass
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.